In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Antibiotics developer Rib-X closes Series B round

Executive Summary

Rib-X Pharmaceuticals (develops antibiotics) grossed $63.5mm from the private sale of Series B preferred stock. New investor Warburg Pincus, which contributed $31mm, led the round.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

UsernamePublicRestriction

Register